<div id="readability-page-1"><div><figure></figure>Home healthcare provider Addus HomeCare will be reporting results this Monday after the bell. Here’s what you need to know. Addus HomeCare beat analysts’ revenue expectations last quarter, reporting revenues of $362.3 million, up 25% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.This quarter, the market is expecting Addus HomeCare’s revenue to grow 25.5% year on year, improving from the 7.5% increase it recorded in the same quarter last year. <figure></figure>Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at Addus HomeCare’s peers in the healthcare providers &amp; services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Brookdale’s revenues decreased 3.4% year on year, missing analysts’ expectations by 1.7%, and Guardant Health reported revenues up 39.4%, topping estimates by 3.5%. Brookdale traded down 9.7% following the results while Guardant Health was also down 3.1%. Read our full analysis of Brookdale’s results here and Guardant Health’s results here.The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare providers &amp; services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. Addus HomeCare is up 4.6% during the same time and is heading into earnings with an average analyst price target of $141 (compared to the current share price of $115.45).</div></div>

ADUS

SBIO

Addus HomeCare is set to report earnings on Monday, with analysts expecting a 25.5% year-on-year revenue growth, up from 7.5% last year. The company previously beat revenue expectations with $362.3 million last quarter. Despite missing estimates multiple times in the past two years, analysts have reaffirmed their forecasts. In the healthcare sector, peers have shown mixed results, with Brookdale's revenues down 3.4% and Guardant Health's up 39.4%. Addus shares are currently at $115.45, with an average analyst price target of $141.

Addus HomeCare Earnings: What To Look For From ADUS